Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Nov 24;60(5):2201678.
doi: 10.1183/13993003.01678-2022. Print 2022 Nov.

Reply to: Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse

Cendrine Godet  1 , Jacques Cadranel  2 , Jean-Pierre Frat  3   4 , Stéphanie Ragot  5   6 , Francis Couturaud  7
Affiliations
Free article
Comment

Reply to: Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse

Cendrine Godet et al. Eur Respir J. .
Free article
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: C. Godet has received speaker fees and travel support from Pfizer and MSD; fees for board memberships from SOS Oxygène and Pulmatrix; grant support from Ohre Pharma, Pfizer, MSD, SOS Oxygène, ISIS Medical and AstraZeneca. J. Cadranel has received speaker fees from MSD and Pfizer on pulmonary aspergillosis and for participating on experts grants on cancer drugs; and grants from Pfizer and SOS Oxygène for study outside the submitted work. J-P. Frat has received grants from the French Ministry of Health, outside the submitted work; grants, personal fees and non-financial support from Fisher & Paykel HealthCare, outside the submitted work; personal fees and non-financial support from SOS Oxygène, outside the submitted work. S. Ragot has no conflict of interest to disclose. F. Couturaud has received research grant support from Bristol-Myers Squibb/Pfizer and fees for board memberships or symposia from Bayer, Bristol-Myers Squibb/Pfizer, Merck Sharp & Dohme and AstraZeneca, and has received travel support from Bayer, Bristol-Myers Squibb/Pfizer, Leo Pharma, Merck Sharp & Dohme and Actelion.

Comment on

  • Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial.
    Godet C, Couturaud F, Marchand-Adam S, Pison C, Gagnadoux F, Blanchard E, Taillé C, Philippe B, Hirschi S, Andréjak C, Bourdin A, Chenivesse C, Dominique S, Bassinet L, Murris-Espin M, Rivière F, Garcia G, Caillaud D, Blanc FX, Goupil F, Bergeron A, Gondouin A, Frat JP, Flament T, Camara B, Priou P, Brun AL, Laurent F, Ragot S, Cadranel J; NebuLamB study group and GREPI network; Godet C, Couturaud F, Cadranel J, Frat JP, Brun AL, Laurent F, Marchand-Adam S, Pison C, Gagnadoux F, Blanchard E, Taillé C, Philippe B, Hirschi S, Andréjak C, Chenivesse C, Dominique S, Bassinet L, Murris-Espin M, Rivière F, Garcia G, Caillaud D, Blanc FX, Goupil F, Gondouin A, Flament T, Camara B, Priou P, Ragot S. Godet C, et al. Eur Respir J. 2022 Jun 16;59(6):2102218. doi: 10.1183/13993003.02218-2021. Print 2022 Jun. Eur Respir J. 2022. PMID: 34764182 Clinical Trial.
  • Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse.
    Liu Y, Lu HW, Xu JF. Liu Y, et al. Eur Respir J. 2022 Nov 24;60(5):2201332. doi: 10.1183/13993003.01332-2022. Print 2022 Nov. Eur Respir J. 2022. PMID: 36137589 No abstract available.

MeSH terms

LinkOut - more resources